Combined Adenovirus-Mediated Nitroreductase Gene Delivery and CB1954 Treatment: A Well-Tolerated Therapy for Established Solid Tumors

This publication has 23 references indexed in Scilit:

• Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954
  Cancer Gene Therapy, 2000
• The potential of acetaminophen as a prodrug in gene-directed enzyme prodrug therapy
  Cancer Gene Therapy, 2000
• Successful use of a plant gene in the treatment of cancer in vivo
  Gene Therapy, 1998
• Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954
  Gene Therapy, 1998
• New Prodrug Activation Gene Therapy for Cancer Using Cytochrome P450 4B1 and 2-Aminoanthracene/4-Ipomeanol
  Human Gene Therapy, 1998
• Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model
  Gene Therapy, 1998
• Gene-Directed Enzyme Prodrug Therapy
  Bioconjugate Chemistry, 1998
• Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination
  Gene Therapy, 1997
• In VivoGene Therapy of Cancer withE. coliPurine Nucleoside Phosphorylase
  Human Gene Therapy, 1997
• Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954
  European Journal Of Cancer, 1995